Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,147
Employees1,147
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,147
Employees1,147

EXEL Key Statistics

Market cap
10.42B
Market cap10.42B
Price-Earnings ratio
18.68
Price-Earnings ratio18.68
Dividend yield
—
Dividend yield—
Average volume
3.51M
Average volume3.51M
High today
$38.96
High today$38.96
Low today
$38.25
Low today$38.25
Open price
$38.65
Open price$38.65
Volume
1.40M
Volume1.40M
52 Week high
$49.62
52 Week high$49.62
52 Week low
$31.90
52 Week low$31.90

EXEL News

Nasdaq 4h
Notable Two Hundred Day Moving Average Cross - EXEL

In trading on Monday, shares of Exelixis Inc (Symbol: EXEL) crossed below their 200 day moving average of $20.64, changing hands as low as $19.20 per share. Exe...

Notable Two Hundred Day Moving Average Cross - EXEL
Simply Wall St 3d
Could Exelixis Pipeline Progress Signal a Turning Point for Revenue Diversification?

Exelixis recently announced detailed results from its pivotal phase 3 STELLAR-303 trial, showing that the investigational therapy zanzalintinib combined with at...

Could Exelixis Pipeline Progress Signal a Turning Point for Revenue Diversification?
Simply Wall St 5d
Exelixis Valuation in Focus After Pivotal Phase 3 Oncology Results

Exelixis (EXEL) just released fresh data from two late-stage clinical trials, capturing the spotlight among oncology investors. The company detailed positive re...

Exelixis Valuation in Focus After Pivotal Phase 3 Oncology Results

Analyst ratings

62%

of 21 ratings
Buy
61.9%
Hold
38.1%
Sell
0%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.
United Therapeutics
VeriSign
Sprouts Farmers Market
Gilead Sciences
Franco-Nevada
Kinross Gold
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.